Tedesco Laura, Valerio Alessandra, Cervino Cristina, Cardile Annalisa, Pagano Claudio, Vettor Roberto, Pasquali Renato, Carruba Michele O, Marsicano Giovanni, Lutz Beat, Pagotto Uberto, Nisoli Enzo
Integrated Laboratories Network, Center for Study and Research on Obesity, Department of Pharmacology, Chemotherapy and Medical Toxicology, School of Medicine, Milan University, Milan, Italy.
Diabetes. 2008 Aug;57(8):2028-36. doi: 10.2337/db07-1623. Epub 2008 May 13.
Cannabinoid type 1 (CB1) receptor blockade decreases body weight and adiposity in obese subjects; however, the underlying mechanism is not yet fully understood. Nitric oxide (NO) produced by endothelial NO synthase (eNOS) induces mitochondrial biogenesis and function in adipocytes. This study was undertaken to test whether CB1 receptor blockade increases the espression of eNOS and mitochondrial biogenesis in white adipocytes.
We examined the effects on eNOS and mitochondrial biogenesis of selective pharmacological blockade of CB1 receptors by SR141716 (rimonabant) in mouse primary white adipocytes. We also examined eNOS expression and mitochondrial biogenesis in white adipose tissue (WAT) and isolated mature white adipocytes of CB1 receptor-deficient (CB1(-/-)) and chronically SR141716-treated mice on either a standard or high-fat diet.
SR141716 treatment increased eNOS expression in cultured white adipocytes. Moreover, SR141716 increased mitochondrial DNA amount, mRNA levels of genes involved in mitochondrial biogenesis, and mitochondrial mass and function through eNOS induction, as demonstrated by reversal of SR141716 effects by small interfering RNA-mediated decrease in eNOS. While high-fat diet-fed wild-type mice showed reduced eNOS expression and mitochondrial biogenesis in WAT and isolated mature white adipocytes, genetic CB1 receptor deletion or chronic treatment with SR141716 restored these parameters to the levels observed in wild-type mice on the standard diet, an effect linked to the prevention of adiposity and body weight increase.
CB1 receptor blockade increases mitochondrial biogenesis in white adipocytes by inducing the expression of eNOS. This is linked to the prevention of high-fat diet-induced fat accumulation, without concomitant changes in food intake.
1型大麻素(CB1)受体阻断可降低肥胖受试者的体重和肥胖程度;然而,其潜在机制尚未完全明确。内皮型一氧化氮合酶(eNOS)产生的一氧化氮(NO)可诱导脂肪细胞的线粒体生物合成及功能。本研究旨在测试CB1受体阻断是否会增加白色脂肪细胞中eNOS的表达及线粒体生物合成。
我们研究了SR141716(利莫那班)对小鼠原代白色脂肪细胞中CB1受体进行选择性药理阻断后对eNOS及线粒体生物合成的影响。我们还检测了CB1受体缺陷(CB1(-/-))小鼠和长期接受SR141716治疗的小鼠在标准或高脂饮食条件下白色脂肪组织(WAT)及分离出的成熟白色脂肪细胞中eNOS的表达及线粒体生物合成情况。
SR141716处理可增加培养的白色脂肪细胞中eNOS的表达。此外,SR141716通过诱导eNOS增加了线粒体DNA含量、参与线粒体生物合成的基因的mRNA水平以及线粒体质量和功能,小干扰RNA介导的eNOS降低可逆转SR141716的作用,从而证明了这一点。高脂饮食喂养的野生型小鼠在WAT及分离出的成熟白色脂肪细胞中eNOS表达及线粒体生物合成降低,而CB1受体基因缺失或长期用SR141716治疗可将这些参数恢复到标准饮食的野生型小鼠所观察到的水平,这一效应与预防肥胖和体重增加有关。
CB1受体阻断通过诱导eNOS的表达增加白色脂肪细胞中的线粒体生物合成。这与预防高脂饮食诱导的脂肪堆积有关,且不伴有食物摄入量的改变。